Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.27 USD | -1.55% | -10.56% | -5.22% |
Apr. 24 | Precigen, Inc. to Present Late-Breaking Abstract for Pivotal Phase 2 Study Data for PRGN- 2012 AdenoVerse Immunotherapy | CI |
Mar. 25 | North American Morning Briefing : Tech in Focus on -2- | DJ |
Financials (USD)
Sales 2024 * | 5.59M | Sales 2025 * | 45.44M | Capitalization | 321M |
---|---|---|---|---|---|
Net income 2024 * | -89M | Net income 2025 * | -73M | EV / Sales 2024 * | 13.4 x |
Net cash position 2024 * | 246M | Net cash position 2025 * | 157M | EV / Sales 2025 * | 3.6 x |
P/E ratio 2024 * |
-3.78
x | P/E ratio 2025 * |
-5.55
x | Employees | 202 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.96% |
Latest transcript on Precigen, Inc.
1 day | -1.55% | ||
1 week | -10.56% | ||
Current month | -3.79% | ||
1 month | -9.93% | ||
3 months | -9.29% | ||
6 months | +16.51% | ||
Current year | -5.22% |
Managers | Title | Age | Since |
---|---|---|---|
Helen Sabzevari
CEO | Chief Executive Officer | 62 | 19-12-31 |
Harry Thomasian
DFI | Director of Finance/CFO | 62 | 21-09-30 |
Randal Kirk
CHM | Chairman | 70 | 08-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randal Kirk
CHM | Chairman | 70 | 08-01-31 |
Dean Mitchell
BRD | Director/Board Member | 68 | 09-02-28 |
Jeffrey Perez
PRN | Corporate Officer/Principal | 52 | 14-07-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 1.27 | -1.55% | 1,123,845 |
24-05-09 | 1.29 | -3.01% | 746,366 |
24-05-08 | 1.33 | -3.62% | 790,077 |
24-05-07 | 1.38 | -4.17% | 908,892 |
24-05-06 | 1.44 | +1.41% | 595,701 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.22% | 321M | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- PGEN Stock